Profiling RNA from Tumor and Normal Samples

The 20 normal and tumor specimens involved in this study were collected and processed as part of the development and verification of a clinical test. All samples were de-identified and the publication of resultant data was approved by the Mayo Clinic Institutional Review Board. Total RNA was extracted from solid tumor tissue and whole blood using the Qiagen® miRNeasy Micro and Mini kits, respectively. Cell lines for this study were created from residual patient tumor tissue except Kasumi-1, KU812, (ATCC®) and Karpas 299 (Sigma-Aldrich®) which were obtained commercially. UHR (Universal Human Reference RNA) was purchased from Agilent (Santa Clara, CA). UHR is a mixture of cell lines derived from breast adenocarcinoma, hepatoblastoma, cervix adenocarcinoma, testis embryonal carcinoma, gliobastoma, melanoma, liposarcoma, histiocytic lymphoma, lymphoblastic leukemia and plasmocytoma. FASTQ sequencing files for Human U-251 MG brain glioblastoma cell lines (GBM) [11 (link)] were obtained from SRA under accession SRP023548.